[Immune reconstitution in advanced ovarian cancer patients undergoing first line chemotherapy].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
; 25(11): 1023-5, 2009 Nov.
Article
em Zh
| MEDLINE
| ID: mdl-19900373
ABSTRACT
AIM:
We investigated the numbers and proportions of lymphocyte subsets in advanced ovarian cancer patients undergoing chemotherapy, so as to identify whether there is immune reconstitution after chemotherapy, and seek rational chemo-immunotherapy strategies in ovarian cancer treatment.METHODS:
Blood samples from each ovarian cancer patient were obtained before (S(0)) and at day 5-7 (S(1)), day 12-14 (S(2)) and day 25-28 (S(3)) after chemotherapy in 13 patients. Flow cytometry technique was employed to analyse the numbers, proportions of CD3(+), CD4(+), CD8(+), CD4(+) CD25(+) Treg and memory-like phenotype lymphocyte subsets.RESULTS:
Lymphopenia was observed at S1 after chemotherapy, but lymphocytes were found gradually recovered after S1. The numbers of CD3(+), CD4(+), CD8(+) T cells and CD4(+) CD25(+) Treg cells reduced to the lowest on S(1). The proportions of CD8(+) T cells and CD4(+) CD25(+) Treg cells reduced to the lowest on S(1) and S(2) respectively. The proportions of CD45RO(+) memory T cells increased significantly on S(2) while the proportion of CD8(+) CD45RA(+) T cells decreased remarkably on S(2).CONCLUSION:
Paclitaxel and carboplatin induce lymphopenia at day 5-7 after chemotherapy, then comes the temporary immune reconstitution. It probably turns out that the "window period" during immune reconstitution offers a best opportunity for cancer immunotherapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Animals
/
Female
/
Humans
/
Middle aged
Idioma:
Zh
Revista:
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
China